MNNGF (Baijin Life Science Holdings) Tax Provision : $-0.34 Mil (TTM As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Baijin Life Science Holdings Tax Provision?

Baijin Life Science Holdings's tax provision for the six months ended in Sep. 2024 was $-0.34 Mil. Its tax provision for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.34 Mil.

Baijin Life Science Holdings Tax Provision Historical Data

The historical data trend for Baijin Life Science Holdings's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Baijin Life Science Holdings Tax Provision Chart

Baijin Life Science Holdings Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Tax Provision

Get a 7-Day Free Trial

-0.18

0.04

Baijin Life Science Holdings Semi-Annual Data
	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24
Tax Provision	Get a 7-Day Free Trial															-	-	-	-	-0.34

Baijin Life Science Holdings Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Sep. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.34 Mil.

Baijin Life Science Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Cyclical » Retail - Cyclical » Baijin Life Science Holdings Ltd (OTCPK:MNNGF) » Definitions » Tax Provision

Traded in Other Exchanges

01466:Hong Kong

Address

66 Gloucester Road, Office B, 9/F Pico Tower, Wanchai, Hong Kong, HKG

Website

http://www.affluent-partners.com

Baijin Life Science Holdings Ltd is positioned as a biopharmaceutical company dedicated in anti-aging and preventive medicine, as well as cellular precision therapy. The company produces health products that are affordable for the general public. The business segments of the company are Life Science segment which includes cellular technology-based services, provide including cellular drugs R&D, large molecule drugs R&D, clinical research services and R&D and sales on self-owned skincare brand, and Fine Jewelry segment that focuses on the procurement, processing, design, production and wholesale distribution of pearls and fine jewelry products.